Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.
Suzette Girgis(Centre Hospitalier Universitaire de Nantes), Jenna D. Goldberg(Centre Hospitalier Universitaire de Nantes), Brandi Hilder(Sheba Medical Center), Damien Fink(Janssen (United States)), Shun Xin Wang Lin(Centre Hospitalier Universitaire de Nantes), Diego Vieyra(Janssen (United States)), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Kodandaram Pillarisetti(Johnson & Johnson (United States)), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Jeffery S. Russell(University of Utah), Yang Chen(Janssen (United States)), Xin Miao(Johnson & Johnson (United States)), Jennifer Smit(Janssen (United States)), Arnob Banerjee(Johnson & Johnson (United States)), Tineke Casneuf(Argenx (Belgium))
Cited by 5
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
|Journal of Clinical Oncology|2022|647
Cutting Edge: The Transcription Factor Eomesodermin Enables CD8+ T Cells To Compete for the Memory Cell Niche
|The Journal of Immunology|2010|417